Mien-Chie Hung, PhD, Oral History Interview, March 7, 2014
Download Full Interview Transcript (1.1 MB)
Major Topics Covered:
- Personal and educational background; witty and humorous personal stories
- Experiences of a Chinese immigrant and foreign graduate student
- The working strategies, inspirations, and commitment of a basic/translational scientist
- Research: signaling pathways and genes,
- Department of Molecular and Cellular Oncology: history, evolution, personal vision for Research culture at MD Anderson
- Vice President of Basic Research
- The Institute for Basic Science
- Effective leadership and mentoring
- Training young scientists
The Historical Resources Center, Research Medical Library, The University of Texas Cancer Center
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, University of Texas System. M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute at Houston, University of Texas M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute
History of Science, Technology, and Medicine | Oncology | Oral History
Hung, Mien-Chie PhD and Rosolowksi, Tacey A. PhD, "Mien-Chie Hung, PhD, Oral History Interview, March 7, 2014" (2014). Interview Sessions. 153.
Conditions Governing Access
About the Interview
About the Interview Subject:
Mien-Chie Hung, PhD (b. 4 September 1950, Taiwan, Republic of China) came to MD Anderson in 1986 as an Assistant Professor in the Department of Tumor Biology and in the Graduate School of Biomedical Science. In 1992, Dr. Hung was the first to show that the adenovirus type EA1 gene has antitumor activity in HER2/neu cancer cells. Dr. Hung has been recognized internationally for his work on signaling transduction pathways of tyrosine kinase growth factor receptors and molecular mechanisms of oncogenes, including transformation and tumorigenesis. He has long been involved in translational research, and has developed therapies for breast, ovarian and pancreatic cancer. Since 2000 he has served as Chair of the Department of Molecular and Cellular Oncology. In 2010 he was appointed Vice President for Basic Research. As of February 2018, Dr. Hung was serving as Chair of the Department of Molecular and Cellular Oncology.